@entity4089 is associated with reproductive acyclicity in zoo African elephants ( @entity16870 ) and may contribute to the non-self-sustainability of the captive population in North America. It is a common cause of @entity249 in @entity1 and other mammals and can be treated with the @entity935 agonist @entity9229 . The objectives of this study were to assess @entity68296 responses to @entity9229 treatment in hyperprolactinemic, acyclic African elephants and to determine the subsequent impact on ovarian cyclic activity. Five elephants, diagnosed as hyperprolactinemic (>11 ng/ml @entity68296 ) and acyclic (maintenance of baseline progestagens for at least 1 yr), were treated with 1-2 mg @entity9229 orally twice weekly for 16-82 wk. @entity9229 reduced (P < 0.05) serum @entity68296 concentrations during the treatment period compared to pretreatment levels in four of five elephants (11.5 +/- 3.2 vs. 9.1 +/- 3.4 ng/ml; 20.3 +/- 16.7 vs. 7.9 +/- 9.8 ng/ml; 26.4 +/- 15.0 vs. 6.8 +/- 1.5 ng/ml; 42.2 +/- 22.6 vs. 18.6 +/- 8.9 ng/ml). However, none of the females resumed @entity43 based on serum progestagen analyses up to 1 yr posttreatment. In addition, within 1 to 6 wk after cessation of oral @entity9229 , serum @entity68296 concentrations returned to concentrations that were as high as or higher than before treatment (P < 0.05). One @entity7105 that exhibited the highest pretreatment @entity68296 concentration (75.2 +/- 10.5 ng/ml) did not respond to @entity9229 and maintained elevated levels throughout the study. Thus, oral @entity9229 administration reduced @entity68296 concentrations in elephants with @entity4089 , but there was no resumption of @entity43 , and a significant @entity68296 rebound effect was observed. It is possible that higher doses or longer treatment intervals may be required for @entity9229 treatment to result in permanent suppression of @entity68296 secretion and to mitigate associated ovarian cycle problems.

Recurrence of @entity4089 and continuation of ovarian acyclicity in captive African elephants ( XXXX ) treated with @entity9229 .

@entity1 :: ('9606', 'Species') :: ['women'] @entity4089 :: ('MESH:D006966', 'Disease') :: ['Hyperprolactinemia', 'hyperprolactinemia'] @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cyclicity'] @entity9229 :: ('MESH:C047047', 'Chemical') :: ['Cabergoline', 'cabergoline'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity16870 :: ('9785', 'Species') :: ['Loxodonta africana'] @entity7105 :: ('9783', 'Species') :: ['elephant'] @entity68296 :: ('100654812', 'Gene') :: ['prolactin']
@entity16870 :: (9785,Species) :: ['Loxodonta africana']
